Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, first-in-human dose-escalation study of SHJ002
Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration
of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional
children will receive the highest tolerated concentration for 28 days.